Overview

Dr. Cudkowicz is a neurologist who specializes in the care of people with amyotrophic lateral sclerosis (ALS). She is actively pursuing research to discover new treatments for people with ALS and related disorders.

Departments

Neurology

Clinical Interests
  • Amyotrophic lateral sclerosis
  • Neurodegenerative disorders
  • Neuromuscular disorders
  • Clinical research
  • Experimental therapeutics
Medical Education
  • MD, Harvard Medical School
  • Residency, Massachusetts General Hospital
  • Fellowship, Massachusetts General Hospital
Board Certifications
  • Neurology
Foreign Languages
  • Italian
Locations
  • Boston: Massachusetts General Hospital
Patient Gateway
Yes, learn more
Insurances Accepted
  • Aetna Health Inc.
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • Cigna (PAL #'s)
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • MassHealth
  • Medicare
  • Medicare - ACD
  • Neighborhood Health Plan - ACD
  • Neighborhood Health Plan - PBO
  • OSW - Connecticut
  • OSW - Maine
  • OSW - New Hampshire
  • OSW - New York
  • OSW - Rhode Island
  • OSW - Vermont
  • Private Health Care Systems (PHCS)
  • Railroad Medicare
  • Railroad Medicare - ACD
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.

Patient Age Group
Adult
Gender
Female

Edit Profile

Biography

Dr. Merit Cudkowicz is the Julieanne Dorn Professor of Neurology at Harvard Medical School, Chief of Neurology Service at Massachusetts General Hospital. Dr. Cudkowicz’s research and clinical activities are dedicated to the study and treatment of people with amyotrophic lateral sclerosis (ALS). Dr. Cudkowicz directs the MGH ALS Program and the MGH Neurological Clinical Research Institute. She is one of the founders and former co-directors of the Northeast ALS Consortium (NEALS), a group of over 100 clinical sites in the United States, Canada, Europe and the Middle East dedicated to performing collaborative academic led clinical trials and research studies in ALS. In conjunction with the NEALS consortium, she planned and completed over 15 multi-center clinical research studies s in ALS. She is Principal Investigator of the Clinical Coordination Center for the National Institute of Neurological Disorders and Stroke’s Neurology Network of Excellence in Clinical Trials (NeuroNEXT). The NeuroNEXT network is an efficient phase II network to develop innovative and new treatments for people with neurological disorders.

Dr. Cudkowicz received the American Academy of Neurology 2009 Sheila Essay ALS award. She is a pioneer in promoting and developing more efficient methods of developing new therapies for people with ALS. A dedicated educator, Dr. Cudkowicz mentors many young neurologists in clinical investigation of ALS and related neurodegenerative disorders. Dr. Cudkowicz completed her undergraduate degree in chemical engineering at Massachusetts Institute of Technology and obtained a medical degree in the Health Science and Technology program of Harvard Medical School. She served her internship at Beth Israel Hospital in New York and her neurology residency and fellowship at MGH. She also obtained a master’s degree in Clinical Epidemiology from the Harvard School of Public Health.

Edit Profile

Research & Publications

Research Summary

My research activities are dedicated to the study and treatment of patients with amyotrophic lateral sclerosis (ALS) and other neurological disorders. As Director of the MGH Neurological Clinical Research Institute and the Principal Investigator for the NINDS supported NeuroNEXT Clinical Coordinating center (www.neuronext.org), I help design human clinical trials to evaluate the safety and effectiveness of therapies that have shown promise in preclinical studies. In ALS, I co-founded an international consortium to test novel therapies in ALS, the Northeast ALS (NEALS) consortium. The NEALS consortium consists of over 100 clinical sites in the United States and Canada dedicated to performing joint academic led clinical trials in ALS. We completed several multi-center clinical trials in ALS. We are leading several new trials in ALS. There is a critical need in neurology for highly trained clinical investigators who work collaboratively with basic scientists to develop new therapeutic strategies. Through NeuroNEXT, I help investigators design clinical trials and learn how to lead multicenter clinical research studies.  

Publications

Cudkowicz ME, Shefner JM, Simpson E, Grasso D, Yu H, Zhang H, Shui A, Schoenfeld D, Brown RH, Wieland S, Barber JR and the Northeast ALS Consortium. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in ALS. Muscle and Nerve 2008;38 (1):837-44.

Cudkowicz ME, Andres PL, Macdonald SA, et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler 2009;10 (2):99-106.

Aggarwal S, Zinman, L, Simpson E, McKinley J, Jackson KE, Pinto H, Conwit RA, Schoenfeld D, Shefner J, Cudkowicz M and the Northeast ALS and Canadian ALS Consortia Clinical Trial Testing Lithium in ALS Terminates Early for Futility. Lancet Neurology 2010: In Press.

Edit Profile

News & Events

Multimedia

  • Respiratory Assistance Video

    A video for ALS patients discussing and demonstrating uses of bipap and cough assist machines.

  • Neurology Bicentennial Celebration, 2011 Part II

    Neurology Bicentennial Celebration, October 13, 2011. Clinical and research presentations on ALS, Stroke, Alzheimer’s Disease, and Parkinson’s Disease

  • Ceftriaxone Trial Video

    A video explaining the design and scientific rationale behind the Clinical Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig's disease.

  • The Clinical Trial of Ceftriaxone in ALS

    A webinar recording explaining the design and scientific rationale behind the Clinical Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig's disease.

Contact

Neurology Associates
15 Parkman Street
Boston, MA 02114-3117
Phone: 617-724-3914
Fax: 617-726-5346

Edit Profile